Relmada Therapeutics RLMD Institutional Ownership

Updated Oct 10, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD) appeared in the 13F filings of 127 institutional investors for the quarter ended June 30, 2026.

• Together they owned 89.83% of the outstanding stock in Q2 2026, up from 79.76% a quarter earlier.
• Total shares held in RLMD rose 20.67% from Q1 2026; the number of holders rose 159.18% from Q2 2025.
• Among the 127 holders of Relmada Therapeutics, 83 added to their positions, 22 reduced their stakes and 22 left their positions unchanged.
• Combined, institutional investors held 100.95Mn shares of RLMD as of Q2 2026, up 17.29Mn from the prior quarter and up 95.65Mn from a year earlier.
• Jupiter Topco LLC led 13F holders of RLMD with 11.16Mn shares as of June 30, 2026, or 9.94% of shares outstanding.
• The largest position increases in RLMD for Q2 2026 were by BlackRock, Inc. (+6.14Mn shares), Jones Hill Capital LP (+3.31Mn shares), State Street Corp (+2.16Mn shares), Venrock Adviser, LLC (+2Mn shares) and Geode Capital Management, LLC (+1.64Mn shares).
• Holders that trimmed the most shares of Relmada Therapeutics in Q2 2026 while keeping a position were Marshall Wace, LLP (-2.23Mn shares), Millennium Management LLC (-1.55Mn shares), Squadron Capital Management LLC (-1.12Mn shares), OrbiMed Advisors LLC (-1.08Mn shares) and Susquehanna International Group, LLP (-981.46K shares).
• Business Quant data shows the 10 biggest positions in Relmada Therapeutics as of Q2 2026 were held by Jupiter Topco LLC (11.16Mn shares), BlackRock, Inc. (7.43Mn shares), Squadron Capital Management LLC (7.35Mn shares), Venrock Adviser, LLC (6.84Mn shares), Spruce Street Capital LP (6.39Mn shares), Adage Capital Partners GP, L.L.C. (4.76Mn shares), Vanguard Capital Management LLC (4.46Mn shares), Jones Hill Capital LP (3.66Mn shares), OrbiMed Advisors LLC (3.63Mn shares) and State Street Corp (2.52Mn shares).